论文部分内容阅读
目的 探讨外周血干细胞移植 (PBSCT)治疗白血病和乳腺癌的临床应用。方法 对5例患者进行PBSCT,采集的单个核细胞悬液于4℃保存48～54h ,分别采用MAC、CEP及CBE方案作移植前预处理。结果 5例患者均获得造血重建。1例慢性粒细胞白血病患者于异基因PBSCT(Allo-PBSCT)后 +12天DNA指纹图提示供者的干细胞植活 ,+28天Ph染色体消失 ,+202天bcr/abl融合基因转阴。 结论 非低温 (4℃ )保存外周血干细胞 ,在自体PBSCT中可以运用 ;CBE方案作Allo-PBSCT预处理 ,其免疫抑制及抗白血病作用确实可靠 ,毒性反应可以耐受 ;DNA指纹图案可以作为Allo-PBSCT早期植活指标
Objective To explore the clinical application of peripheral blood stem cell transplantation (PBSCT) in the treatment of leukemia and breast cancer. Methods Five patients were treated with PBSCT. The mononuclear cell suspensions were collected and stored at 4°C for 48-54 hours. MAC, CEP, and CBE protocols were used for pretreatment. Results Hematopoietic reconstitution was achieved in all 5 patients. One case of chronic myelogenous leukemia patients after allogeneic PBSCT (Allo-PBSCT) +12 days DNA fingerprinting revealed that the donor’s stem cells were engrafted, Ph chromosome disappeared on +28 days, and bcr/abl fusion gene turned negative on +202 days. Conclusion Non-hypothermal (4°C) preservation of peripheral blood stem cells can be used in autologous PBSCT. The CBE protocol is pretreated with Allo-PBSCT. Its immunosuppressive and anti-leukemic effects are reliable and the toxicity response can be tolerated; DNA fingerprinting can be used as Allo -PBSCT early planting index